Home

Hologic, Inc. - Common Stock (HOLX)

72.80
+1.22 (1.70%)

Hologic Inc. is a global medical technology company focused on improving women's health through the development and delivery of innovative products and solutions

The company specializes in diagnostic, surgical, and medical imaging systems, with a particular emphasis on breast health, cervical health, and skeletal health. Hologic's offerings include advanced molecular diagnostics, imaging systems for breast cancer detection, and various surgical instruments and techniques that enhance patient care. With a commitment to advancing health outcomes for women, Hologic actively invests in research and development to address unmet medical needs and improve access to vital healthcare solutions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Hologic (NASDAQ:HOLX) Reports Q4 In Line With Expectations But Full-Year Sales Guidance Misses Expectations
Medical technology company Hologic (NASDAQHOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the other hand, next quarter’s revenue guidance of $1 billion was less impressive, coming in 3.2% below analysts’ estimates. Its non-GAAP profit of $1.03 per share was 1.4% above analysts’ consensus estimates.
Via StockStory · February 5, 2025
Hologic Q1 Earnings Assessmentbenzinga.com
Via Benzinga · February 5, 2025
Hologic Earnings Report: Q1 Overviewbenzinga.com
Via Benzinga · February 5, 2025
Hologic Earnings Review: Q1 Summarybenzinga.com
Via Benzinga · February 5, 2025
Earnings Scheduled For February 5, 2025benzinga.com
Via Benzinga · February 5, 2025
5 Analysts Have This To Say About Hologicbenzinga.com
Via Benzinga · February 3, 2025
Friday's pre-market session: top gainers and losers in the S&P500 indexchartmill.com
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session.
Via Chartmill · January 31, 2025
How Is The Market Feeling About Hologic?benzinga.com
Via Benzinga · January 23, 2025
Peering Into Hologic's Recent Short Interestbenzinga.com
Via Benzinga · December 18, 2024
5 S&P 500 Stocks Set To Shine In The Final Week Of January — If History Repeats Itselfbenzinga.com
S&P 500 surges to record highs in final week of January as investors react to economic optimism, Trump's leadership, and AI investments.
Via Benzinga · January 23, 2025
FDA Warns Hologic Over BioZorb Manufacturing Violationsbenzinga.com
FDA issues warning to Hologic, citing manufacturing and safety violations for BioZorb devices. Patient safety risks and reporting failures highlighted
Via Benzinga · January 17, 2025
This James Hardie Industries Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · December 10, 2024
Expert Ratings For Hologicbenzinga.com
Via Benzinga · December 10, 2024
Peering Into Hologic's Recent Short Interestbenzinga.com
Via Benzinga · November 27, 2024
Looking Into Hologic's Recent Short Interestbenzinga.com
Via Benzinga · November 6, 2024
Assessing Hologic: Insights From 10 Financial Analystsbenzinga.com
Via Benzinga · October 4, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth $1,600 Todaybenzinga.com
Via Benzinga · September 30, 2024
Critical Insights From Hologic Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · September 17, 2024
Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?benzinga.com
The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of Election Day on Tuesday.
Via Benzinga · November 4, 2024
Hologic Recalls Soft Tissue Marker Device BioZorb, FDA Issues Warning After Almost 400 Complaintsbenzinga.com
FDA and Hologic advise health providers to return all unused BioZorb Markers due to adverse events, including pain and infection.
Via Benzinga · October 25, 2024
Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatmentsbenzinga.com
Hologic Inc. is acquiring Gynesonics for $350 million, adding the Sonata System to its fibroid treatment lineup. The acquisition aims to boost Hologic's women's health offerings and expand minimally invasive solutions.
Via Benzinga · October 14, 2024
Here's How Much You Would Have Made Owning Hologic Stock In The Last 20 Yearsbenzinga.com
Via Benzinga · September 12, 2024
Peering Into Hologic's Recent Short Interestbenzinga.com
Via Benzinga · September 2, 2024
Here's How Much You Would Have Made Owning Hologic Stock In The Last 10 Yearsbenzinga.com
Via Benzinga · August 19, 2024
Analyst Scoreboard: 8 Ratings For Hologicbenzinga.com
Via Benzinga · August 16, 2024